SYS-CON MEDIA Authors: Pat Romanski, Elizabeth White, Glenn Rossman, Cynthia Dunlop, Peter Silva

News Feed Item

People With Type 2 Diabetes Achieve Superior Outcomes With Insulin Pumps vs. Multiple Daily Injections

Comparative Efficacy Results From the OpT2mise Trial Published in The Lancet Could Redefine Management of Insulin-Requiring Type 2 Diabetes

BRAMPTON, ON--(Marketwired - July 02, 2014) - As an example of its commitment to improving clinical outcomes for all people with diabetes, Medtronic, Inc. (NYSE: MDT) today announced the results of the global OpT2mise trial, which included eight participating centres in Canada. The results showed that MiniMed insulin pumps safely achieve better glucose control for people with insulin-requiring type 2 diabetes than multiple daily injections. While the benefits of continuous subcutaneous insulin infusion (CSII) with an insulin pump for people with type 1 diabetes are well proven, this is the largest global study to evaluate the comparative efficacy of CSII with an insulin pump versus multiple daily insulin injections in people with type 2 diabetes with poor glycemic control. Study results were published online in The Lancet today.

In the OpT2mise trial, those using insulin pumps achieved a mean A1C (average blood glucose) reduction of 1.1 percent compared to only a 0.4 percent reduction by those using multiple daily injections. This improvement in glucose control was achieved without any episodes of severe hypoglycemia. In addition, those in the insulin pump group lowered the total daily dose of insulin by more than 20 percent. There was no difference in weight gain between the two groups.

Reducing A1C is critical for people with diabetes because even small percent drops aid significantly in preventing complications, such as eye disease, kidney disease, nerve damage and heart attacks1, 2.

 "For these patients, insulin pump technology is therefore a valuable option with proven benefits over simply continuing adjustments of an MDI (multiple daily injection) regimen," said Dr. Ronnie Aronson of LMC Diabetes & Endocrinology, Toronto, Canada, one of the study authors. "Insulin pump use can safely reduce HbA1c, with less insulin, and without increasing hypoglycemia and should take a spot in the care path for our type 2 diabetes patients who need advanced insulin management." 

Approximately 20 million people around the world with type 2 diabetes require insulin replacement therapy and adherence to insulin therapy can be a challenge, with 57% of patients on MDI therapy admitting to omitting insulin injections3.

The global, randomized, controlled study was sponsored by Medtronic and conducted with participation from 331 patients, ranging in age from 30 to 75 years. Eight centres across Canada participated in the study. Specific results include:

  • Those using insulin pumps demonstrated a mean reduction of A1C levels by 1.1 percent, vs. only 0.4 percent for participants using multiple daily injections (< 0.001).
  • Those in the CSII arm experienced the A1C reduction without any episodes of severe hypoglycemia (low blood sugar, which can cause confusion, disorientation, loss of consciousness, and in the worst cases coma and even death) or ketoacidosis (a potentially life-threatening condition caused by hyperglycemia or high blood sugar).
  • The total daily insulin dose was 20.4% lower with CSII than with injection therapy (< 0.001) with no significant difference in body weight change between the two groups.
  • The percentage of participants in the CSII group achieving an A1C < 8% was twice that of the multiple daily injections group (55% vs. 28%).

"As Medtronic continues to expand into providing more solutions for people living with type 2 as well as type 1 diabetes, collaborating with the world's experts to build a clinical body of evidence to help guide therapy for all people with diabetes is very important," said Francine R. Kaufman, M.D., Chief Medical Officer and Vice President of Global, Clinical and Medical Affairs for Medtronic Diabetes. "OpT2mise is the latest example of this clinical leadership and a trial that has the potential to help improve access to insulin pump technology for the many people with type 2 diabetes who could benefit."

About the Diabetes Business at Medtronic of Canada

The Diabetes business at Medtronic of Canada (www.medtronicdiabetes.ca) is the Canadian leader in advanced glucose monitoring and control solutions, including insulin pump technology, continuous glucose monitoring systems and therapy management software, as well as world-class, 24/7 consumer and professional service and support. 

About Medtronic of Canada

Medtronic of Canada Ltd. (www.medtronic.ca) is a trusted Canadian leader delivering innovative health system solutions and advanced medical technologies to alleviate pain, restore health, and extend life in the areas of cardiovascular medicine, diabetes, spinal and neurosurgery, and ear, nose, throat surgery. Medtronic is proud to employ more than 700 Canadians. Headquartered in Brampton, Ontario, Medtronic has regional offices in Vancouver and Montreal, including a manufacturing facility, Medtronic CryoCath, located in Pointe-Claire, Quebec.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853

2 The post trial monitoring results: 10 years follow up:
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW (2008). 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med; 359:1577-1589

3 Peyrot et al (2010) Correlates of insulin injection omission, Diabetes Care 33:240-245.

Contact:
Melicent Lavers-Sailly
Public Relations
905-460-3653

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an In...
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud...
In her General Session at 15th Cloud Expo, Anne Plese, Senior Consultant, Cloud Product Marketing, at Verizon Enterprise, will focus on finding the right mix of renting vs. buying Oracle capacity to scale to meet business demands, and offer validated Oracle database TCO models for Oracle development and testing environments. Anne Plese is a marketing and technology enthusiast/realist with over 19...
StackIQ offers a comprehensive software suite that automates the deployment, provisioning, and management of Big Infrastructure. With StackIQ’s software, you can spin up fully configured big data clusters, quickly and consistently — from bare-metal up to the applications layer — and manage them efficiently. Our software’s modular architecture allows customers to integrate nearly any application wi...
As Platform as a Service (PaaS) matures as a category, developers should have the ability to use the programming language of their choice to build applications and have access to a wide array of services. Bluemix is IBM's open cloud development platform that enables users to easily build cloud-based, creative mobile and web applications without having to spend large amounts of time and resources o...
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at Internet of @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, will discuss how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will nee...
When you set off to build an app that will change the world, designing your system architecture to be reliable and scalable is important but the stark reality is that, for your MVP, you probably had a “need for speed” (of development). You didn’t know what all the axes were to scale your application, where your stress points would be, and what weird and wonderful ways your customers would use it d...
Compute virtualization has been transformational, yet security policy implementation and enforcement has lagged behind in agility and automation. There are a number of key considerations when implementing policy in private and hybrid clouds. In his session at 15th Cloud Expo, Holland Barry, VP of Technology at Catbird, will discuss the impact of this new paradigm and what organizations can do to...
Samsung VP Jacopo Lenzi, who headed the company's recent SmartThings acquisition under the auspices of Samsung's Open Innovaction Center (OIC), answered a few questions we had about the deal. This interview was in conjunction with our interview with SmartThings CEO Alex Hawkinson. IoT Journal: SmartThings was developed in an open, standards-agnostic platform, and will now be part of Samsung's Ope...
SYS-CON Events announced today that Red Hat, the world's leading provider of open source solutions, will exhibit at Internet of @ThingsExpo, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Red Hat is the world's leading provider of open source software solutions, using a community-powered approach to reliable and high-performing cloud, Linux, ...